B-cell development stage is a challenge and vulnerability ... "Once we determine the pathways involved, we can find new drug combinations to improve treatment outcomes." ...

The Epstein-Barr virus — a well-established risk factor for MS — is able to alter the movements of immune cells, a new study ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

There is substantial interest in the development of therapeutic approaches to treat IgG-mediated autoimmune diseases that target B ... pathways of immunity associated with myeloid cells.

Monoclonal B-cell lymphocytosis is when your body produces ... A family history of cancer has been highly connected to the development of CLL. Research suggests that 13% to 18% of people develop ...

ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the two announcements, the company’s stock, ...